Choice of parenteral solutions for correcting metabolic acidosis.

M. D. Brown

1979-04-01

Abstract:

What problem does this paper attempt to address?

Clinical Significance of Circulating Tumor DNA in Neoadjuvant-Treated HER2-negative Luminal B Breast Cancer.

Yunxiang Zhou,Zhiyun Zhang,Ting Ma,Huihui Chen,Lu Shen,Shijie Wu,Xianan Guo,Kexin Liu,Weina Mu,Yuyang Miao,Yiding Chen

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e12616

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:e12616 Background: Circulating tumor DNA (ctDNA) holds significant value in the comprehensive management of breast cancer (BC) patients, whereas long-standing questions have been raised concerning the practical utility of ctDNA in HR+/HER2- subtype. Herein, we evaluated the clinical activity of ctDNA in luminal B (HR+/HER2-, with either Ki67≥20% and/or PR<20%) BC patients receiving neoadjuvant therapy. Methods: Patients received neoadjuvant chemotherapy (NCT) or neoadjuvant endocrine therapy combined with CDK4/6 inhibitors (NET) were enrolled. Tumor tissue and plasma samples were collected and subjected to sequencing. Blood was collected for ctDNA analysis before treatment (T0), 2-3 weeks after treatment (T1), at the midpoint of neoadjuvant treatment (T2), prior to surgery (S), and postoperatively (PO). The tumor tissues were biopsied or surgically excised at T0, T1, and S to assess somatic mutation profiling and pathological markers. NGS assays were performed with a custom-designed panel that covered 769 cancer-related genes. Results: As of Jan 7, 2024, 448 tumor tissue and plasma samples from 80 BC patients undergoing NCT (n = 57) or NET (n = 23) were sequenced and analyzed. At T0, positive ctDNA was detected in 62.8% (49/78, another two failed quality control) of the patients. Furthermore, ctDNA detection and the higher concentration had a significant correlation with clinicopathologic characteristics that confer aggressiveness, including larger tumor size, more lymph node metastases, and lower hormone receptor expression. There was also a certain relativity between ctDNA positivity and tumor grading as well as MammaPrint index ( P < 0.1). With the progression of neoadjuvant therapy, the ctDNA positive rate decreased over time (T1: 32/80, 40.0%; T2: 11/61, 18.0%; S: 7/65, 10.8%; and PO: 6/64, 9.4%). Although no correlation was found between pretherapeutic Ki67 expression and T0 ctDNA status ( P = 0.871), the Ki67 expression in early cycles of neoadjuvant therapy (T1) was significantly higher in patients with inter-therapeutic detectable ctDNA. Moreover, the expression and decline of Ki67 after neoadjuvant therapy were significantly correlated with ctDNA positivity at T2, S, and PO. Among the patients who had undergone surgery, 8 patients were classified as RCB 0/1 and the rest 57 as RCB 2/3. All patients who exhibited RCB 0/1 were ctDNA negative at S and PO. Compared to RCB 2/3, patients with RCB 0/1 tumors showed a significant increase in ctDNA concentration at T0 ( P = 0.027). Subgroup analysis revealed similar trends in ctDNA status and concentration changes in the NCT group and NET group. Conclusions: We reported an unprecedented baseline ctDNA positivity in luminal B BC, and the ctDNA levels were closely associated with the clinicopathologic characteristics of patients. As the research progresses, more predictive and prognostic information is expected to be discovered. Clinical trial information: NCT05649475 .
Clinical use of circulating tumor DNA analysis in patients with lymphoma

Bettina Bisig,Karine Lefort,Sylvain Carras,Laurence de Leval

DOI: https://doi.org/10.1016/j.humpath.2024.105679

IF: 3.526

2024-11-04

Human Pathology

Abstract:The analysis of circulating tumor DNA (ctDNA) in liquid biopsy specimens has an established role for the detection of predictive molecular alterations and acquired resistance mutations in several tumors. The low-invasiveness of this approach allows for repeated sampling and dynamic monitoring of disease evolution. Originating from the entire body tumor bulk, plasma-derived ctDNA reflects intra- and interlesional genetic heterogeneity. In the management of lymphoma patients, ctDNA quantification at various timepoints of the patient's clinical history is emerging as a complementary tool that may improve risk stratification, assessment of treatment response and early relapse detection during follow-up, most prominently in patients with diffuse large B-cell lymphoma or classic Hodgkin lymphoma. While liquid biopsies have not yet entered standard-of-care treatment protocols in these settings, several trials have provided evidence that at least a subset of lymphoma patients may benefit from the introduction of liquid biopsies into daily clinical care. In parallel, continuous technological developments have enabled highly sensitive ctDNA assessment methods, which span from locus-specific techniques identifying single hotspot mutations, to sequencing panels and genome-wide approaches that explore broader genetic and epigenetic alterations. Here, we provide an overview of current methods and ongoing technical developments for ctDNA evaluation. We also summarize the most important data from a selection of clinical studies that have explored the clinical use of ctDNA in several lymphoma entities.

pathology
[A family of lysophospholipid receptors].

N. Fukushima

2000-09-01

Seikagaku. The Journal of Japanese Biochemical Society

Abstract:
Circulating Tumor DNA in Lymphoma

Swetha Kambhampati,Jasmine Zain

DOI: https://doi.org/10.1007/s11899-022-00677-1

Abstract:Purpose of review: Recent advances have been made in circulating tumor DNA (ctDNA), the method to minimally invasive detect lymphoma sensitively with tumor-derived DNA in the blood of patients with lymphomas. This article discusses these various methods of ctDNA detection and the clinical context in which they have been applied to for a variety of lymphoma subtypes. Recent findings: ctDNA has been applied to a variety of subtypes of lymphoma and has been used in the context of genotyping somatic mutations and classification of disease, monitoring of response during treatment, detecting minimal residual disease even with radiographic remission, and predicting relapse and long-term survival outcomes. There are a variety of techniques used to measure ctDNA including digital polymerase chain reaction and next-generation sequencing techniques including high-throughput variable-diversity-joining rearrangement sequencing, high-throughput sequencing of somatic mutations, and Cancer Personalized Profiling by deep sequencing. While the greatest data has been generated in diffuse large B cell lymphoma, there have been studies utilizing application of ctDNA in follicular lymphoma, mantle cell lymphoma, Hodgkin's lymphoma, peripheral T cell lymphoma, and primary CNS lymphoma among others. ctDNA is an emerging biomarker in lymphoma that can minimally invasively provide further genotypic information, diagnostic clarification, and treatment prognostication by detection of minimal residual disease even without radiographic evidence of disease. Future studies are needed to standardize the use of ctDNA and translate its use clinically for the management of lymphoma patients.
Prevention of early familial maladjustment by parent-staff group meetings: influence of familial background.

J. Allain,J. Bernard,D. Frommel,Y. Laurian,J. Proust

DOI: https://doi.org/10.1111/J.1600-0609.1984.TB02548.X

2009-04-24

Abstract:The possibility of preventing some major familial maladjustment following the diagnosis of severe haemophilia in the frame of free discussion group was explored. Five couples, 3 with a familial history of haemophilia and 2 without met 5 times over a 2 year period with 3 staff members for a full day. Transcripts of tape recorded sessions were analyzed. Parents with no familial history were apparently more affected but had a more dynamic approach towards hemophilia than the others. They benefited more from the program. Four of the five families were able to treat their child at home before 4 years of age. This new approach seems to help parents to adjust to this severe chronic disease and staff members to reconsider their interaction with parents.
Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes

Jin Ju Kim,Hye Min Kim,Hongkyung Kim,Soo-Jeong Kim,Seung-Tae Lee,Jong Rak Choi,Saeam Shin,Doh Yu Hwang

DOI: https://doi.org/10.4143/crt.2023.667

Abstract:Purpose: We designed and evaluated the clinical performance of a plasma circulating tumor DNA (ctDNA) panel of 112 genes in various subtypes of lymphoma. Materials and methods: Targeted deep sequencing with an error-corrected algorithm was performed in ctDNA from plasma samples that were collected before treatment in 42 lymphoma patients. Blood buffy coat was utilized as a germline control. We evaluated the targeted gene panel using mutation detection concordance on the plasma samples with matched tissue samples analyzed the mutation profiles of the ctDNA. Results: Next-generation sequencing analysis using matched tissue samples was available for 18 of the 42 patients. At least one mutation was detected in the majority of matched tissue biopsy samples (88.9%) and plasma samples (83.3%). A considerable number of mutations (40.4%) that were detected in the tissue samples were also found in the matched plasma samples. Majority of patients (21/42) were diffuse large B cell lymphoma patients. The overall detection rate of ctDNA in patients was 85.7% (36/42). The frequently mutated genes included PIM1, TET2, BCL2, KMT2D, KLHL6, HIST1H1E, and IRF8. A cutoff concentration (4,506 pg/mL) of ctDNA provided 88.9% sensitivity and 82.1% specificity to predict ctDNA mutation detection. The ctDNA concentration correlated with elevated lactate dehydrogenase level and the disease stage. Conclusion: Our design panel can detect many actionable gene mutations, including those at low frequency. Therefore, liquid biopsy can be applied clinically in the evaluation of lymphoma patients, especially in aggressive lymphoma patients.
Surface morphology and kinetic roughening of Ag on Ag(111) studied with scanning tunneling microscopy.

Heyvaert,Krim,Van Haesendonck C,Bruynseraede

DOI: https://doi.org/10.1103/PHYSREVE.54.349

1996-07-01

Abstract:The topography of Ag grown on Ag~111! measured with scanning tunneling microscopy reveals threedimensional, layered islands for film thicknesses below 500 A. For thicker Ag films, the layered structures can no longer be observed. The induced surface roughness increases with increasing film thickness and corresponds to the formation of self-similar surfaces with roughness exponents H close to 1 for thicknesses up to 5000 A. Our results are compared to the relevant theoretical models. @S1063-651X~96!11307-6#
Thallium Lung-to-Heart Quantification: Three Methods of Evaluation

M. Harler,M. Mahoney,Bruce E. Bartlett,K. Patel,E. Turbiner

1986-12-01

Abstract:201 TI stress test images, has been found useful in diagnosing cardiac dysfunction. We evaluated three methods of quantification in terms of inter- and intraobserver variability and reproducibility. Fifty anterior 201 TI stress images were quantified by each of the following methods: Method A (sum region), which involved one region of interest (ROI) in the measurement of pul monary activity relative to that of the myocardium; Method B (count density), which required two ROis, the lung-to-heart ratio being dependent on count density; and Method C (maximum pixel), which used the gray scale of the computer to determine the most intense pixels in the lung field and myocardium. Statistical evaluation has shown that the three methods assess clinical data equally well. Method C was found to be most reproducible in terms of inter- and intraobserver variability (p = 0.0016 and 0.0083), followed by Meth ods A (p = 0.0026 and 0.0129) and B (p = 0.0038 and 0.0135). Al though nearly equivalent in terms of statistics, the three methods possess inherent differences and therefore should not be used inter changeably without conversion factors. Thallium-201 stress test imaging is useful in detecting coronary artery disease (CAD); as an adjunct to this examination, the lung-to-heart ratio provides additional knowledge of cardiac function. Previous studies suggest that increased pulmonary 201 Tl activity immediately after stress correlates with an increase in CAD (1). Furthermore, the lung to-heart ratio is held to be very specific for advanced CAD because increased activity appears to be a function of increased pulmonary capillary wedge pressures, reflecting development of transient, exercise-induced left ventricular failure (2). Given the clinical significance of the lung-to-heart ratio, we have evaluated three methods of quantification in terms of inter and intraobserver variability and reproducibility.
Prognostication with circulating tumor DNA: is it ready for prime time?

David M Kurtz,David M. Kurtz

DOI: https://doi.org/10.1182/hematology.2019000013

IF: 2.264

2019-12-06

Hematology

Abstract:Abstract Emerging methods to detect tumor-derived DNA in the blood plasma of patients with lymphomas—so-called “circulating tumor DNA” (ctDNA)—have the potential to change the way in which lymphoma is diagnosed and managed in the clinic. The possible applications for ctDNA are numerous, including mutation genotyping, response monitoring, and detection of minimal residual disease during a time of radiographic remission. This article discusses the methodology for detecting ctDNA in aggressive B-cell lymphomas, including digital polymerase chain reaction, targeted sequencing of immunoglobulin receptors, and targeted next-generation sequencing. The advantages of each of these methods are also compared, with a focus on promising clinical applications. These include identification of molecular subtypes (eg, cell-of-origin and double-hit lymphomas) from pretreatment plasma, molecular response prediction after an initial course of therapy, and early detection of relapsing disease prior to clinical relapse. Finally, this article discusses the challenges in implementing ctDNA assays in the clinic today, including possible solutions to these challenges.

hematology
Natural mixtures of persistent organic pollutants (POPs) suppress ovarian follicle development, liver vitellogenin immunostaining and hepatocyte proliferation in female zebrafish (Danio rerio).

Marianne Kraugerud,R. Doughty,J. Lyche,V. Berg,N. H. Tremoen,P. Alestrøm,M. Aleksandersen,E. Ropstad

DOI: https://doi.org/10.1016/j.aquatox.2012.02.031

IF: 5.202

2012-07-15

Aquatic Toxicology

Abstract:
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

Eliza M. Lauer,Jurik Mutter,Florian Scherer

DOI: https://doi.org/10.1038/s41375-022-01618-w

2022-06-15

Leukemia

Abstract:Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA) profiling has become a potential novel strategy for patient management in B-cell lymphoma. Emerging innovative therapeutic options and an unprecedented growth in our understanding of biological and molecular factors underlying lymphoma heterogeneity have fundamentally increased the need for precision-based tools facilitating personalized and accurate disease profiling and quantification. By capturing the entire mutational landscape of tumors, ctDNA assessment has some decisive advantages over conventional tissue biopsies, which usually target only one single tumor site. Due to its non- or minimal-invasive nature, serial and repeated ctDNA profiling provides a real-time picture of the genetic composition and facilitates quantification of tumor burden any time during the course of the disease. In this review, we present a comprehensive overview of technologies used for ctDNA detection and genotyping in B-cell lymphoma, focusing on pre-analytical and technical requirements, the advantages and limitations of various approaches, and highlight recent advances around improving sensitivity and suppressing technical errors. We broadly review potential applications of ctDNA in clinical practice and for translational research by describing how ctDNA might enhance lymphoma subtype classification, treatment response assessment, outcome prediction, and monitoring of measurable residual disease. We finally discuss how ctDNA could be implemented in prospective clinical trials as a novel surrogate endpoint and be utilized as a decision-making tool to guide lymphoma treatment in the future.

oncology,hematology
Circulating Tumor DNA: Clinical Roles in Diffuse Large B Cell Lymphoma

Fang-Tian Wu,Luo Lu,Wei Xu,Jian-Yong Li

DOI: https://doi.org/10.1007/s00277-018-3529-9

2018-01-01

Annals of Hematology

Abstract:Diffuse large B cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma (NHL), is a clinically and molecularly heterogeneous malignant lymphoproliferative disease. In the era of personalized medicine, genetic information is critical to early diagnosis, aiding risk stratification, directing therapeutic option, and monitoring disease relapse. However, lacking a circulating disease with most DLBCL cases hampers the acquisition of tumor genomic landscapes and disease dynamics. Circulating tumor DNA (ctDNA) is a novel noninvasive, real-time, and tumor-specific biomarker, reliably reflecting the comprehensive tumor genetic profiles, thus holds great promise in individualized medicine, including precise diagnosis and prognosis, response monitoring, and relapse detection of DLBCL. Here, we reviewed the recent advances of ctDNA in DLBCL and discussed its clinical values at different time points during the disease courses by comparing with the current routine methods in clinical practice. Collectively, we anticipated that ctDNA will ultimately be integrated into the management of DLBCL to facilitate precision medicine.
Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas

Mary Kwok,S Peter Wu,Clifton Mo,Thomas Summers,Mark Roschewski

DOI: https://doi.org/10.1007/s11864-016-0425-1

Abstract:The goal of therapy for aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is to achieve cure. Combination chemotherapy with rituximab cures most patients, but those with recurrent disease have a poor prognosis. Medical imaging scans such as computed tomography (CT) and positron emission tomography (PET) are the principal methods to assess response and monitor for disease relapse after therapy but are fundamentally limited by risks of radiation, cost, and a lack of tumor specificity. Novel sequencing-based DNA monitoring methods are capable of quantifying small amounts of circulating tumor DNA (ctDNA) before, during, and after therapy for mature B-cell lymphomas. Detection of ctDNA encoding clonal rearranged variable-diversity-joining (VDJ) receptor gene sequences has demonstrated improved analytical sensitivity and enhanced tumor specificity compared to imaging scans in DLBCL, offering broad clinical applicability across a range of aggressive B-cell lymphomas. Molecular monitoring of ctDNA has vaulted into the spotlight as a promising non-invasive tool with immediate clinical impact on monitoring for recurrence after therapy prior to clinical symptoms. As these clinical observations are validated, ctDNA monitoring needs to be investigated as a tool for response-adapted therapy and as a marker of minimal residual disease upon completion of therapy in aggressive B-cell lymphomas. Molecular monitoring of ctDNA holds tremendous promise that may ultimately transform our ability to monitor disease in aggressive B-cell lymphomas.
The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas

Xiaoping Zhang,Li Yang,Minyi Zhu,Xiaotian Zhao,Yao Xiao,Jiaohui Pang,Liuqing Zhu,Qiuxiang Ou,Hai-Wen Ni,Jingyan Xu

DOI: https://doi.org/10.1080/14796694.2024.2402209

Abstract:Aim: Advances in circulating tumor DNA (ctDNA) analysis for diffuse large B-cell lymphoma (DLBCL) have prompted the evaluation of its utility in other non-Hodgkin lymphomas (NHLs), leading to significant insights into its potential applications.Methods: We retrospectively studied paired plasma and tissue/bone marrow biopsies of 203 non-DLBCL NHLs [87 follicular lymphomas (FL), 64 mantle cell lymphomas (MCL), 30 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL) and 22 marginal zone lymphomas (MZL)]. Genomic profiling was performed using a targeted next generation sequencing panel (Hemasalus™). Longitudinal analyses were performed to explore plasma ctDNA utility in disease monitoring.Results: High plasma ctDNA detection rates were observed across NHL subtypes (FL: 88.5%, MCL: 90.6%, CLL/SLL: 100%, MZL: 68.2%), with high concordance of actionable mutations (FL: 87.4%, MCL: 93.8%, CLL/SLL: 93.3%, MZL: 81.8%) and multiple genetic aberrations exclusively identified in plasma. Particularly, IGH-BCL2 and IGH-CCND1 fusions were concordant between plasma and tumor biopsies in FLs (91.1%) and MCLs (91.3%), respectively. Longitudinal data demonstrated that ctDNA clearance correlated with complete response but ctDNA increases preceded radiological relapses.Conclusion: ctDNA exhibited high concordance with tumor biopsy in detecting genetic aberrations and demonstrated potential as a promising noninvasive approach to disease surveillance in non-DLBCL NHLs.
The role of myocardial membrane lipids in the development of cardiac necrosis.

S. Gudbjarnason,J. Hallgrímsson

DOI: https://doi.org/10.1111/J.0954-6820.1976.TB05862.X

2009-04-24

Abstract:1. The fatty acid composition of cardiac membrane lipids is influenced by age, sex, diet and other factors. 2. The relative amounts of various polyunsaturated fatty acids in cardiac lipids influence markedly the development of myocardial necrosis and mortality following overstimulation with isoproterenol. 3. The availability and metabolism of arachidonic acid may play an important role in regulation of cardiac metabolism.
Liquid biopsy in lymphoma: Molecular methods and clinical applications

Melita Cirillo,Alexander F M Craig,Sven Borchmann,David M Kurtz

DOI: https://doi.org/10.1016/j.ctrv.2020.102106

Abstract:In this article, we broadly review the application of cfDNA analysis to the diagnosis and management of lymphoma. We introduce the advantages of cfDNA measurement over conventional tissue biopsy and describe how cfDNA may be utilized for both genotyping and detection of minimal residual disease. First, we discuss genotyping, beginning with differences in identifying mutations from the blood plasma vs. from circulating cells. We review the technical distinctions between PCR- and NGS-based assays and describe two important applications of NGS-based cfDNA tests, namely the identification of resistance mutations and classification of disease subtype. We discuss difficulties in genotyping diseases with low burden of tumor cells and the application of cfDNA assays in these contexts. Second, we describe the utility of ctDNA measurement in assessing MRD. We cover recent advances in the assessment of pre-treatment disease burden as a prognostic biomarker, detection of molecular response to therapy, and early detection of relapsing disease. Third, we explore select emerging areas of research in ctDNA technologies that show promise in boosting the performance of existing ctDNA-based assays. These include cell-free DNA fragment structure analysis or 'fragmentomics', epigenetic modifications, and novel circulating analytes such as tumor-educated platelets and extracellular vesicular DNA. We also discuss alternative analytes to blood plasma for tumor detection, such as urine, saliva, and stool. Finally, we present a case that highlights potential applications of ctDNA approaches to the management of patients with lymphoma, while also defining important prerequisite advances before this can be fully realized. We close with a look to the future of cfDNA applications, outlining one potential timeline and path forward towards routine clinical application.
Circulating tumor DNA in NK/T and peripheral T cell lymphoma

Yu-Jia Huo,Wei-Li Zhao

DOI: https://doi.org/10.1053/j.seminhematol.2023.07.003

IF: 3.754

2023-07-01

Seminars in Hematology

Abstract:Natural killer (NK)/T-cell lymphomas (NK/TCL) and peripheral T-cell lymphomas (PTCL) are aggressive hematological malignancies. With the development of next-generation sequencing, circulating tumor DNA (ctDNA) can be detected by several techniques with clinical implications. So far, the effect of ctDNA in pretreatment prognosis prediction, longitudinal monitoring of treatment response and surveillance of long-term remission or relapse in NK/TCL and PTCL has been reported in several researches.

hematology
Updates on Circulating Tumor DNA Assessment in Lymphoma

Justin M Darrah,Alex F Herrera

DOI: https://doi.org/10.1007/s11899-018-0468-4

Abstract:Purpose of review: The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. Recent findings: Recent studies have demonstrated the use of ctDNA assessment across many lymphoma subtypes including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin lymphoma, and T-cell lymphoma. In addition, many novel applications of ctDNA assessment have been described such as the development of new prognostic models, investigation of clonal evolution and heterogeneity, early assessment of treatment response, and prediction of response to targeted therapy as a form of personalized medicine. The use of ctDNA has been shown to be feasible across many lymphoma subtypes and has shown significant promise for several new applications. Additional studies will be needed to validate these findings prior to routine use in clinical practice.
Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes

Haisheng Liu,Yue Yuan,Lili Wu,Lanping Diao,Yuhuan Gao,Chengcheng Wang,Pingping Zou,Shanbo Cao,Jiayue Qin

DOI: https://doi.org/10.1182/blood-2023-180642

IF: 20.3

2023-11-28

Blood

Abstract:Introduction Genotyping plays an important role in the diagnosis, risk stratification and treatment response surveillance of lymphoma, a disease with considerable heterogeneity in clinical and pathological characteristics. To date, tumor tissue biopsy based genotyping is still considered as gold standard in lymphoma, but its application is hampered by the invasive nature and imperfect performance in capturing spatial and temporal tumor heterogeneity. Circulating tumor DNA (ctDNA), which is shed into peripheral blood by apoptotic or necrotic tumor cells, has shown the potential as a noninvasive alternative to tumor tissue DNA (tDNA) for molecular profiling. Many efforts have been made to investigate the feasibility of ctDNA based on next-generation sequencing (NGS) in lymphoma, but most of the studies were conducted in Caucasian population and limited to B-cell lymphoma patients. In the present study, we evaluated the performance of plasma-derived ctDNA against tDNA based genotyping across multiple lymphoma subtypes. Methods Between 4/2021 and 5/2023, a total of 110 patients were enrolled in this study. Matched tumor tissue biopsies and peripheral blood were collected at diagnosis. Both tDNA and ctDNA were extracted and subjected to a targeted capture NGS assay covering the entire coding region or recurrently mutated region of 196 genes. The mean coverage depth was 2431x and 2513x for tDNA and ctDNA, respectively. The limit of detection (LOD) was 1% and 0.5% for tDNA and ctDNA, respectively. Results The enrolled cohort comprised of 63 (57.3%) male and 47(42.7%) female patients, with a median age of 58 years old (range 1.25-89). Among the 110 patients, the most prevalent subtype is diffuse large B-cell lymphoma (DLBCL,n=45), following by angioimmunoblastic T-cell lymphoma (AITL, n=16), anaplastic large cell lymphoma (ALCL, n=13) , mantle cell lymphoma (MCL, n=10), follicular lymphoma (FL, n=9), primary mediastinal large B-cell lymphoma (PMBL, n=9), extranodal natural killer/T cell lymphoma (ENKTL, n=4), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, n=4). For further analysis, DLBCL, MCL, FL and PMBL were categorized as B-cell lymphoma group (n=73), while AITL, ALCL, ENKTL and PTCL-NOS were categorized as T-cell lymphoma group (n=37). Mutations were detected in 109(99.10%)tDNA and 110(100%)ctDNA, respectively. A total of 1586 mutations involving 177 genes were detected in tDNA, and the median number of mutations per sample was 12 (range 0-62), with KMT2D (39.09%), KMT2C (30.90%), IGLL5 (30.00%), TET2 (25.45%) and TP53 (20.90%) being the top 5 mutated genes. For ctDNA, a total of 1750 mutations involving 178 genes were detected and the median number of mutations per sample was 14 (range 2-63), with KMT2D (37.27%), KMT2C (29.09%), IGLL5 (27.27%), TET2 (25.45%) and DNMT3A (27.27%) being the top 5 mutated genes. To determine the concordance of mutations detected in tDNA and ctDNA, sensitivity was calculated utilizing tDNA as gold standard. The overall sensitivity of ctDNA based genotyping was 85.39% (95%CI: 82.36%-88.41%), with B-cell lymphoma showing a slightly higher sensitivity than T-cell lymphoma (86.17%, 95%CI: 83.51%-88.83% vs. 83.84%, 95%CI: 76.30%-91.32%). In terms of subtypes, PTCL-NOS exhibited the highest sensitivity (89.58%, 95%CI: 56.43%-122.73%, while AITL exhibited the lowest sensitivity (78.53%, 95%CI: 64.09%-92.97%) (Figure 1A). In addition, the difference of mutational spectrum between B-cell lymphoma and T-cell lymphoma was precisely depicted by ctDNA based genotyping. We discovered mutations in TET2, RHOA, and PLCG1 were significantly present in T-cell lymphoma, while mutations in MYD88, CD79B, CARD11, CREBBP, MYC, PIM1, IGLL5, ATM, SOCS1 and HIST1HIE were significantly enriched in B-cell lymphoma (Figure 1B). Conclusion In the present study, recurrent mutations across a variety of lymphoma subtypes were identified by ctDNA based genotyping, which were in high concordance with tDNA based genotyping. These data demonstrated that ctDNA based genotyping is a reliable noninvasive alternative to tumor tissue biopsy for molecular profiling of lymphoma patients, especially for patients whose tissues are not accessible for genotyping.

hematology
Application of circulating tumor DNA in lymphoma

Chun-ji Gao,Shu Fang

DOI: https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.01.013

2018-01-20

Abstract:Circulating cell-free DNA (cfDNA) has been found in both healthy individuals and tumor patients, while circulating tumor DNA (ctDNA) existed only in peripheral blood of tumor patients. Recent studies in lymphoma have confirmed, compared to other clinical markers, ctDNA is qualified with high sensitivity, specificity and little trauma. It may also be a good marker for the detection of minimal residual disease (MRD). Thus, ctDNA may become a novel molecular marker for prediction, detection and surveillance of lymphoma. Key words: Lymphoma; Diagnosis; Prognosis; Circulating tumor DNA

Medicine

Choice of parenteral solutions for correcting metabolic acidosis.

Clinical Significance of Circulating Tumor DNA in Neoadjuvant-Treated HER2-negative Luminal B Breast Cancer.

Clinical use of circulating tumor DNA analysis in patients with lymphoma

[A family of lysophospholipid receptors].

Circulating Tumor DNA in Lymphoma

Prevention of early familial maladjustment by parent-staff group meetings: influence of familial background.

Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes

Surface morphology and kinetic roughening of Ag on Ag(111) studied with scanning tunneling microscopy.

Thallium Lung-to-Heart Quantification: Three Methods of Evaluation

Prognostication with circulating tumor DNA: is it ready for prime time?

Natural mixtures of persistent organic pollutants (POPs) suppress ovarian follicle development, liver vitellogenin immunostaining and hepatocyte proliferation in female zebrafish (Danio rerio).

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research

Circulating Tumor DNA: Clinical Roles in Diffuse Large B Cell Lymphoma

Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas

The role of myocardial membrane lipids in the development of cardiac necrosis.

Liquid biopsy in lymphoma: Molecular methods and clinical applications

Circulating tumor DNA in NK/T and peripheral T cell lymphoma

Updates on Circulating Tumor DNA Assessment in Lymphoma

Validation of Circulating Tumor DNA As an Alternative to Tumor Tissue Biopsy in Genotyping across Multiple Lymphoma Subtypes

Application of circulating tumor DNA in lymphoma